Alnylam Pharmaceuticals (NASDAQ:ALNY) Stock Bumped Down to “Market Perform” by Sanford C. Bernstein

Alnylam Pharmaceuticals (NASDAQ:ALNY) was downgraded by research analysts at Sanford C. Bernstein from an “outperform” rating to a “market perform” rating in a research report issued on Friday, Marketbeat Ratings reports. They presently have a $199.00 price objective on the biopharmaceutical company’s stock. Sanford C. Bernstein‘s target price would suggest a potential upside of 12.28% from the company’s current price.

Several other analysts have also recently weighed in on the company. JPMorgan Chase & Co. dropped their price target on Alnylam Pharmaceuticals from $375.00 to $369.00 and set an “overweight” rating for the company in a report on Wednesday, September 30th. Weiss Ratings reissued a “hold (c)” rating on shares of Alnylam Pharmaceuticals in a research report on Thursday. Wall Street Zen downgraded shares of Alnylam Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Sunday, August 2nd. Oppenheimer lowered their price target on shares of Alnylam Pharmaceuticals from $500.00 to $350.00 and set an “outperform” rating on the stock in a research report on Friday, July 31st. Finally, Bank of America reiterated a “buy” rating and issued a $287.00 price objective on shares of Alnylam Pharmaceuticals in a research note on Friday. Two analysts have rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and nine have assigned a Hold rating to the company. Based on data from MarketBeat, Alnylam Pharmaceuticals has an average rating of “Moderate Buy” and a consensus target price of $334.48.

Alnylam Pharmaceuticals Stock Up 1.9%

ALNY stock traded up $3.24 during midday trading on Friday, hitting $177.24. The company’s stock had a trading volume of 371,324 shares, compared to its average volume of 1,486,453. The company’s fifty day moving average price is $237.78 and its 200 day moving average price is $287.22. The company has a debt-to-equity ratio of 0.75, a current ratio of 3.05 and a quick ratio of 2.99. Alnylam Pharmaceuticals has a twelve month low of $170.69 and a twelve month high of $479.79. The stock has a market capitalization of $23.72 billion, a P/E ratio of 33.10 and a beta of 0.28.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last announced its quarterly earnings results on Thursday, October 29th. The biopharmaceutical company reported $16.26 EPS for the quarter, beating analysts’ consensus estimates of $1.66 by $14.60. The firm had revenue of $1.46 billion during the quarter, compared to analysts’ expectations of $1.43 billion. Alnylam Pharmaceuticals had a net margin of 15.26% and a return on equity of 84.93%. The company’s revenue for the quarter was up 16.7% compared to the same quarter last year. During the same quarter last year, the company posted $2.90 earnings per share. As a group, equities research analysts predict that Alnylam Pharmaceuticals will post 6.43 EPS for the current year.

Insider Buying and Selling at Alnylam Pharmaceuticals

In other Alnylam Pharmaceuticals news, EVP Bryan Supran sold 1,758 shares of the stock in a transaction that occurred on Friday, October 2nd. The shares were sold at an average price of $226.88, for a total transaction of $398,855.04. Following the completion of the sale, the executive vice president owned 12,807 shares of the company’s stock, valued at approximately $2,905,652.16. This represents a 12.07% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. 0.86% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the business. GraniteShares Advisors LLC boosted its holdings in Alnylam Pharmaceuticals by 12.7% during the 3rd quarter. GraniteShares Advisors LLC now owns 1,825 shares of the biopharmaceutical company’s stock worth $450,000 after acquiring an additional 205 shares during the last quarter. Traynor Capital Management Inc. grew its stake in shares of Alnylam Pharmaceuticals by 22.6% in the 3rd quarter. Traynor Capital Management Inc. now owns 12,818 shares of the biopharmaceutical company’s stock worth $3,163,000 after acquiring an additional 2,360 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. purchased a new stake in shares of Alnylam Pharmaceuticals in the third quarter valued at about $18,226,000. Profund Advisors LLC raised its holdings in shares of Alnylam Pharmaceuticals by 22.5% in the third quarter. Profund Advisors LLC now owns 16,919 shares of the biopharmaceutical company’s stock valued at $4,175,000 after purchasing an additional 3,105 shares during the last quarter. Finally, ProShare Advisors LLC lifted its position in shares of Alnylam Pharmaceuticals by 4.2% during the third quarter. ProShare Advisors LLC now owns 133,935 shares of the biopharmaceutical company’s stock valued at $33,047,000 after purchasing an additional 5,421 shares in the last quarter. 92.97% of the stock is owned by institutional investors.

Alnylam Pharmaceuticals News Roundup

Here are the key news stories impacting Alnylam Pharmaceuticals this week:

• Positive Sentiment: Alnylam reported third-quarter revenue of $1.46 billion, up 16.7% year over year and ahead of the $1.43 billion consensus estimate. Reported earnings of $16.26 per share also exceeded expectations, while the company maintained its fiscal 2026 product-sales outlook. Alnylam Pharmaceuticals third-quarter earnings report
• Positive Sentiment: Management projects 2026 TTR product sales of approximately $4.2 billion to $4.5 billion, supported by continued demand for Amvuttra. The company also reaffirmed its development plans for nucresiran and expanded the TRITON-CM study to roughly 2,250 patients while maintaining an expected launch timeframe around 2030. Alnylam TTR sales and TRITON-CM update
• Positive Sentiment: The quarter’s earnings included a substantial tax benefit, reportedly contributing roughly $1.9 billion to the unusually large EPS beat. Analysts also cited encouraging brezosiran data as a potential source of longer-term value. Alnylam Q3 tax benefit and earnings analysis
• Neutral Sentiment: Trading in ALNY was temporarily halted under a volatility-related LULD pause, reflecting unusually sharp market activity following the earnings release.
• Negative Sentiment: The large EPS beat was driven heavily by the tax windfall rather than recurring operating performance. Investors may therefore place greater weight on product sales and forward guidance than on reported earnings.
• Negative Sentiment: Reports indicated that U.S. Amvuttra and Onpattro sales growth slowed, raising concerns about the pace of TTR franchise expansion despite the company’s full-year outlook. Alnylam product sales growth report
• Negative Sentiment: Stifel downgraded Alnylam from Buy to Hold with a $225 price target, while Needham cut its target from $357 to $243, signaling reduced near-term upside and heightened execution concerns. Stifel Alnylam downgrade
• Negative Sentiment: Alnylam’s decision to expand the nucresiran heart trial again increases development costs and may prolong the path to commercialization. Separately, a law firm announced an investigation related to a prior company disclosure, adding a legal-overhang risk. Alnylam nucresiran study update

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc is a biopharmaceutical company focused on developing and commercializing medicines based on RNA interference (RNAi). The company’s therapies are designed to silence specific genes involved in disease, with the goal of addressing the underlying causes of genetic and other serious conditions.

Alnylam’s marketed products include ONPATTRO (patisiran) and AMVUTTRA (vutrisiran) for hereditary transthyretin-mediated amyloidosis, GIVLAARI (givosiran) for acute hepatic porphyria, and OXLUMO (lumasiran) for primary hyperoxaluria type 1.